The award, presented at the meeting of the German Diabetes Society in Berlin in late May, recognises diabetic research internationally. It comes with a prize of 25,000 euros ($A38,000), co-funded by Novo Nordisk.
Professor Jandeleit-Dahm, Deputy Head of the Diabetes Department and who leads Monash’s research program into diabetes and kidney disease, holds the Leibniz Chair for Diabetes Research at the University of Dusseldorf, Germany.
“It’s a very good recognition of our work and also the work we do in our lab in Dusseldorf – it shows we are really getting noticed,” she said. “I’m very pleased and excited to have been awarded it.”
The award particularly recognises the Jandeleit-Dahm group’s work into the enzyme NOX5 as a promising target for diabetic kidney disease treatment. (See story)
Hans Christian Hagedorn was one of Denmark’s leading researchers in the treatment of diabetes. He helped develop the first practical method for determining the concentration of blood glucose in 1917, and in 1922 began collaborating with two others on developing insulin. He co-founded what is today, Novo Nordisk, a leading global healthcare company, and the Novo Nordisk Foundation.
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.